Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Operating Expenses (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Operating Expenses for 13 consecutive years, with $159.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 0.72% year-over-year to $159.2 million, compared with a TTM value of $733.3 million through Dec 2025, up 24.56%, and an annual FY2025 reading of $733.3 million, up 24.56% over the prior year.
  • Operating Expenses was $159.2 million for Q4 2025 at Tandem Diabetes Care, up from $157.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $239.3 million in Q1 2025 and bottomed at $76.5 million in Q1 2021.
  • Average Operating Expenses over 5 years is $139.1 million, with a median of $138.4 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 97.99% in 2023, then tumbled 35.29% in 2024.
  • Year by year, Operating Expenses stood at $101.0 million in 2021, then skyrocketed by 31.99% to $133.3 million in 2022, then decreased by 3.71% to $128.4 million in 2023, then rose by 23.12% to $158.0 million in 2024, then rose by 0.72% to $159.2 million in 2025.
  • Business Quant data shows Operating Expenses for TNDM at $159.2 million in Q4 2025, $157.2 million in Q3 2025, and $177.7 million in Q2 2025.